Zanfina Ademi Delaney | Equity in cardiovascular disease and designing the distributional cost-effectiveness analysis framework to assess novel pharmacological treatments
1. Understanding equity in cardiovascular disease.
2. Assessing the cost-effectiveness of novel pharmacological treatments and designing the distributional cost-effectiveness analysis framework, incorporating equity and ranking interventions based on dominance criteria.
The PhD student will have exposure to world-class health economic modelling techniques and the opportunity to work with the investigator team, primarily supervised by Professor Zanfina Ademi and Dr Jedidiah Morton.
Few studies in Australia look at the cost and disease burden by equity. Moreover, few cost-effectiveness analyses include health equity information. Due to public concerns about health equity, economic evaluation techniques are being challenged to incorporate inequalities. This is to not only ensure that healthcare technologies are being delivered appropriately and according to the best available evidence, but also to address the important issue of allocative efficiency, i.e. the efficient distribution of healthcare resources, considering multiple interventions and opportunity costs.
Applying our innovative health economic model, we will attempt to incorporate equity utilising the distributional cost-effectiveness analysis framework. This will allow us to rank scalable interventions based on dominance criteria and analyse trade-offs that can enhance population health and reduce unfair health inequalities.
Research Placement
Undertake a placement of a defined period in an external institution, either domestic or international, gaining experience in a different research environment that will augment your PhD.